Skip to ContentSkip to Navigation
Rijksuniversiteit Groningenfounded in 1614  -  top 100 university
Over ons Praktische zaken Waar vindt u ons dr. D.G. Knapen

Publicaties

A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors

First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors

Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

Metastatic mismatch repair deficient oesophageal squamous cell carcinoma leading to diagnosis of Lynch syndrome with a complete response to nivolumab treatment

Independent transcriptional patterns reveal biological processes associated with disease-free survival in early colorectal cancer

Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants

Monoclonal antibody biosimilars for cancer treatment

Search for novel cancer treatments and reducing their side effects

Abstract 5611: LAG-3 PET imaging in patients with cancer before immune checkpoint inhibitor therapy

Pers/media

Kanker over praten? #9 Dr. Daan Knapen: hoe de toekmost van behandeling eruit ziet.

Podcast over het coloncarcinoom